Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Ex-KY officer found guilty
Convicted killer clown freed
How to vote
'L.A. Law' actor dies
Body to be flown back to UK
2 officers charged in death
FBI warns of fake videos
Louisiana helicopter crash
NYC declares drought watch
Glenn wins Grand Prix title
Shark severs surfer’s leg
Browns legend Jones dies
Severe storms hit Oklahoma
MrBeast probe findings
Slashes Apple stake again
Gaza resumes polio shots
Files for bankruptcy
US bolsters Middle East
Adams returns to court
ACA enrollment opens
TX citizenship status law
School book bans report
World Series celebration
AP election reporting
Fire closes Ohio River bridge
To close 140 restaurants
$425M military aid to UKR
Iran threatens Israel, US
Announces MLB retirement
Performers announced
WA activates National Guard
PA ballot case ruling
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Stock Tumbles
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by wholesale distributors hurt sales of its diabetes drug Mounjaro and anti-obesity medicine Zepbound.
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.
11d
on MSN
Lilly's weight loss drug shortage deemed over, but hurdles remain
For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's ...
3d
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
5d
on MSN
What You Need To Know Ahead of Eli Lilly's Earnings Wednesday
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
3d
on MSN
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
The American Journal of Managed Care
2d
5 Essential Drugs Currently Facing Shortages
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
3d
on MSN
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
3d
on MSN
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
11d
Shady drugmaker used code words to sell knockoff weight-loss drug: Lawsuit
Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...
Medscape
6d
Battle Continues Over Compounded GLP-1s
Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...
This Is Money on MSN
9d
Can YOU cash in on the pharma giants leading the weight loss boom?
The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback